Glycosmedia

Diabetes News Service

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookies Policy
  • News
  • Archive
  • Categories & Tags
  • Journal Watch
  • Updates
  • Education
  • Reviews
  • About us ▼
    • About Glycosmedia
    • Editorial Team
    • Frequently asked questions
    • Comments
    • Press Releases
    • Disclaimer
  • Subscribe
  • Contact

Diabetes News

Tag: metformin


Role of human organic cation transporter-1 (OCT-1/SLC22A1) in modulating the response to metformin in patients with type 2 diabetes

May 26th 2022

Taken together, our results corroborate the role of OCT-1 in the transport of metformin and also point at OCT1 genetic variations possibly affecting the transport of metformin into the cells and hence its subsequent action in responders and non-responders (BMC Endocrine Disorders)

Categories: Genetics, Medication, News
Tags: metformin, Type 2 Diabetes

Categories: Genetics, Medication
Tags: metformin, Type 2 Diabetes

Cardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes With Sodium–Glucose Cotransporter-2 Inhibitors Versus Metformin

May 25th 2022

As first-line T2D treatment, initiators receiving SGLT-2i showed a similar risk for MI/stroke/mortality, lower risk for HHF/mortality and HHF, and a similar safety profile except for an increased risk for genital infections compared with those receiving metformin (Annals of Internal Medicine)

Categories: Medication, News
Tags: metformin, SGLT2 inhibitors

Categories: Medication
Tags: metformin, SGLT2 inhibitors

Sitagliptin / Metformin hydrochloride Accord

May 24th 2022

On 19 May 2022, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Sitagliptin/Metformin hydrochloride Accord, intended for the treatment of type 2 diabetes mellitus

Categories: Medication, News
Tags: metformin, sitagliptin, Type 2 Diabetes

Categories: Medication
Tags: metformin, sitagliptin, Type 2 Diabetes

Bioequivalence Studies of New Generic Formulations of Vildagliptin and Fixed-Drug Combination of Vildagliptin and Metformin Versus Respective Originator Products in Healthy Volunteers

May 11th 2022

The new generic drug products of vildagliptin and the FDCs of vildagliptin and metformin demonstrated bioequivalence to the approved originator products and are therefore expected to provide similar therapeutic effects (Diabetes Therapy)

Categories: Medication, News
Tags: metformin, vildagliptin

Categories: Medication
Tags: metformin, vildagliptin

Effects of canagliflozin and metformin on insulin resistance and visceral adipose tissue in people with newly-diagnosed type 2 diabetes

February 11th 2022

Canagliflozin reduces visceral adipose tissue and improves blood glucose, insulin resistance and systemic inflammation in people with newly-diagnosed type 2 diabetes (BMC Endocrine Disorders volume)

Categories: Medication, News
Tags: canagliflozin, Insulin resistance, metformin, Type 2 Diabetes

Categories: Medication
Tags: canagliflozin, Insulin resistance, metformin, Type 2 Diabetes

Combination Therapy with Pioglitazone/Exenatide Metformin Reduces the Prevalence of Hepatic Fibrosis and Steatosis: The Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT) Trial

January 13th 2022

(i) At EOS T2DM subjects treated with Triple Therapy had less hepatic steatosis and fibrosis versus Conventional Therapy; (ii) severity of hepatic steatosis and fibrosis both were strongly and inversely correlated with insulin resistance; (iii) changes in liver fibrosis scores (APRI, NFS, FIB-4, AST/ALT ratio) have limited value in predicting response to therapy (Diabetes, Obesity and Metabolism)

Categories: Medication, News
Tags: exantide, fibrosis, hepatic steatosis, metformin, pioglitazone, steatosis

Categories: Medication
Tags: exantide, fibrosis, hepatic steatosis, metformin, pioglitazone, steatosis

Effect of Maternal Metformin Treatment in Pregnancy on Neonatal Metabolism: Evidence From Newborn Metabolic Screening

October 21st 2021

We have identified subtle (nonpathological) changes in neonatal metabolism that represent a signature effect of fetal metformin exposure (Diabetes Care)

Categories: Gestational, Medication, News
Tags: metformin

Categories: Gestational, Medication
Tags: metformin

Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine

September 5th 2021

In patients with type 2 diabetes and preserved renal function treatment with M+I resulted in reduction of renal perfusion and increase in vascular resistance, in contrast to treatment with E+I that preserved renal perfusion and reduced vascular resistance (Cardiovascular Diabetology)

Categories: Medication, Nephropathy, News
Tags: Empagliflozin, Linagliptin, metformin

Categories: Medication, Nephropathy
Tags: Empagliflozin, Linagliptin, metformin

Effect of Maternal Metformin Treatment in Pregnancy on Neonatal Metabolism: Evidence From Newborn Metabolic Screening

September 3rd 2021

We have identified subtle (nonpathological) changes in neonatal metabolism that represent a signature effect of fetal metformin exposure (Diabetes Care)

Categories: Gestational, News
Tags: metformin

Categories: Gestational
Tags: metformin

Metformin for pediatric obesity and insulin resistance: a retrospective study within an integrated health care system

August 10th 2021

Metformin with lifestyle interventions significantly reduced weight, BMI, and BMI z score in pediatric patients with obesity and insulin resistance up to 24 months, compared with intensive and routine counseling alone (Obesity)

Categories: News, Obesity, Paediatrics, Treatment
Tags: metformin

Categories: Obesity, Paediatrics, Treatment
Tags: metformin

Metformin Affects Gut Microbiome Composition and Function and Circulating Short-Chain Fatty Acids: A Randomized Trial

July 21st 2021

Metformin, but not behavioral weight loss, impacted gut microbiota composition at 6 months and 12 months. Both metformin and behavioral weight loss altered circulating SCFAs at 6 months, including increasing acetate, which correlated with lower fasting insulin (Diabetes Care)

Categories: Medication, News
Tags: metformin, microbiome

Categories: Medication
Tags: metformin, microbiome

Effectiveness of antidiabetic agents for treatment of gestational diabetes: A methodological quality assessment of meta-analyses and network meta-analysis

June 28th 2021

This review study of available literature shows that metformin can be a superior option in most neonatal and maternal adverse pregnancy outcomes in women with gestational diabetes mellitus; the results need to be further updated by including future more qualified studies (Journal of Diabetes Investigation)

Categories: Gestational, Medication, News
Tags: metformin

Categories: Gestational, Medication
Tags: metformin

GLP-1 receptor agonists for cardiovascular outcomes with and without metformin. A systematic review and meta-analysis of cardiovascular outcomes trials

June 15th 2021

Subgroup analyses suggested that treatment with GLP-1 RAs has a beneficial effect on cardiovascular outcomes irrespective of baseline use of metformin. However, given the exploratory nature of subgroup analyses, these findings should be treated as hypothesis-generating rather than conclusive evidence (Diabetes Research and Clinical Practice)

Categories: Medication, News
Tags: GLP-1 RA, metformin

Categories: Medication
Tags: GLP-1 RA, metformin

Association of glycemia with insulin sensitivity and β-cell function in adults with early type 2 diabetes on metformin alone

April 7th 2021

Glycemia is strongly associated with β-cell dysfunction in adults with early T2DM treated with metformin alone. Efforts to improve glycemia should focus on interventions aimed at improving β-cell function (Journal of Diabetes and Its Complications)

Categories: News, Pathology
Tags: glycaemic control, metformin, Type 2 Diabetes, β-cell

Categories: Pathology
Tags: glycaemic control, metformin, Type 2 Diabetes, β-cell

Metformin and health outcomes: An umbrella review of systematic reviews with meta‐analyses

March 17th 2021

Observational evidence on metformin seems largely unreliable. Randomized evidence shows benefits for preventing diabetes and in some gynaecological and obstetrical settings. However, almost all meta‐analyses are of low or critically low quality according to AMSTAR 2 criteria (European Journal of Clinical Investigation)

Categories: Medication, News
Tags: metformin

Categories: Medication
Tags: metformin

Gut microbiota compositions and metabolic functions in type 2 diabetes differ with glycemic durability to metformin monotherapy

March 5th 2021

There were different compositions of gut microbiota with unique microbial metabolic pathways between type 2 diabetes with and without glycemic durability to metformin monotherapy. Microbial salvage by increasing thiamine biosynthesis might be beneficial for the metformin durable group to maintain optimal glycemic control (Diabetes Research and Clinical Practice)

Categories: News, Pathology
Tags: gut microbiota, metformin, Type 2 Diabetes

Categories: Pathology
Tags: gut microbiota, metformin, Type 2 Diabetes

Metformin Benefits: Another Example for Alternative Energy Substrate Mechanism?

February 20th 2021

These effects may be considered as being to some extent similar to those produced by SGLT2is, another class of glucose-lowering agents with proven cardiorenal protection. The metabolic effects of metformin and SGLT2is may indeed have some similarities (Diabetes Care)

Categories: Medication, News
Tags: metformin

Categories: Medication
Tags: metformin

Use of Metformin and Cardiovascular Effects of New Classes of Glucose-Lowering Agents: A Meta-analysis of Cardiovascular Outcome Trials in Type 2 Diabetes

January 21st 2021

As strategy-driven, head-to-head RCTs comparing SGLT-2i, GLP-1RA, or DPP-4i with metformin (and their combination with metformin) while ensuring glycemic and weight equipoise are unlikely to become available in the future, sharing and analyzing individual-level data from already conducted RCT would help to inform the evidence for the best first-line treatment(s) in subjects with type 2 diabetes and confirm or refute our finding (Diabetes Care)

Categories: News, Research
Tags: DPP-4i, GLP-1RA, metformin, SGLT2 inhibitors

Categories: Research
Tags: DPP-4i, GLP-1RA, metformin, SGLT2 inhibitors

Metformin Use Is Associated With Reduced Mortality in a Diverse Population With COVID-19 and Diabetes

January 19th 2021

These results suggest that while diabetes is an independent risk factor for COVID-19-related mortality, this risk is dramatically reduced in subjects taking metformin prior to diagnosis of COVID-19, raising the possibility that metformin may provide a protective approach in this high risk population (Frontiers in Endocrinology)

Categories: Medication, News
Tags: COVID-19, metformin

Categories: Medication
Tags: COVID-19, metformin

Dose‐dependent accumulation of glucose in the intestinal wall and lumen induced by metformin as revealed by [18F]fluorodeoxyglucose PET‐MRI

November 25th 2020

Metformin dose is an independent determinant of FDG accumulation in the wall and lumen of the large intestine in individuals treated with this drug (Diabetes, Obesity and Metabolism)

Categories: Medication, News
Tags: metformin

Categories: Medication
Tags: metformin
  • 1
  • 2
  • 3
  • …
  • 7
  • Next Page »

Subscribe

subscribe-iconFREE weekly updates by email Please CLICK HERE

Gold Sponsors

AstraZenecaNovo NordiskNapp DiabetesBoehringer Ingelheim

Silver Sponsors

Welsh Endocrinology and Diabetes Society (WEDS)About Ascensia Diabetes CareAbbott Diabetes Care

FUNDING NOTICE

The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Advertisers

CRC Press

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.

Categories

  • Audits
  • Bariatric
  • Biochemistry
  • Cardiovascular
  • Devices
  • Diagnosis
  • Diet
  • Education
  • Epidemiology
  • Genetics
  • Gestational
  • Guidance
  • Guidelines
  • Hepatology
  • Hypertension
  • Immunology
  • Management
  • Media
  • Medication
  • Meetings
  • Monitoring
  • Nephrology
  • Neuropathy
  • Nephropathy
  • Obesity
  • Ophthalmology
  • Paediatrics
  • Pathology
  • Pharma
  • Pharmacology
  • Physiology
  • Podiatry
  • Prediabetes
  • Prevalence
  • Prevention
  • Psychological
  • Reports
  • Research
  • Screening
  • Sponsorship
  • Technology
  • Testing
  • Transplantation
  • Treatment
  • Wound Care

To see all articles associated with a category just click on the category name.

Popular Tags

ADA BMI canagliflozin CGM CKD closed-loop COVID-19 dapagliflozin DPP4 DPP4 inhibitors Empagliflozin exenatide GLP-1 RA GLP-1RA GLP1 glycaemic control HbA1c heart failure hyperglycemia hypoglycemia incretin insulin insulin pump Insulin resistance Ketoacidosis liraglutide metformin microvascular mortality NAFLD NICE pioglitazone retinopathy semaglutide SGLT2 inhibitors sitagliptin statin sulfonylureas Type 1 Diabetes Type 2 Diabetes

To see all articles associated with a tag just click on the tag name.

Complete list of Tags ››

Join us on Facebook

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

My Tweets

mobileGlycosmedia is also available as an App:

For iPhone and iPad | For Android devices


Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Copyright © 2022 Glycosmedia Partnership